FULVESTRANT FORMULATIONS
Long term storage stable fulvestrant-containing compositions are disclosed. The compositions can include fulvestrant; a solvent selected from dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof; an oil mixture selected from a mixture of caprylic and capric triglycerides, a mixture of caprylic, capric and linoleic triglycerides, a mixture of caprylic, capric and succinic triglycerides, and a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and a sustained release member selected from benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid. The fulvestrant-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.
1 . A fulvestrant-containing composition comprising:
a) fulvestrant;
b) a solvent selected from the group consisting of dimethyl sulfoxide (DMSO), glycofurol, N-methyl pyrrolidone, and mixtures thereof;
c) an oil mixture selected from the group consisting of
i) a mixture of caprylic and capric triglycerides,
ii) a mixture of caprylic, capric and linoleic triglycerides,
iii) a mixture of caprylic, capric and succinic triglycerides, and
iv) a mixture of propylene glycol dicaprylate and propylene glycol dicaprate; and
d) a sustained release member selected from the group consisting of benzyl benzoate, dihydrolipoic acid, benzyl alcohol and lipoic acid; wherein
said fulvestrant-containing composition having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.
2 . The composition of claim 1 , wherein the volume ratio of solvent: oil mixture: sustained release member is about 1 to about 2.5: about 0.9 to about 2.5: about 0.9 to about 2.5.
3 . The composition of claim 2 , wherein the volume ratio of solvent: oil mixture: sustained release member is about 1.3: about 1: about 1.7.
4 . The composition of claim 1 , wherein the solvent is present in an amount of about 33% (v/v), the oil mixture is present in an amount of about 25% (v/v) and the sustained release member is present in an amount of about 42% (v/v).
5 . The composition of claim 1 , wherein the solvent is DMSO.
6 . The composition of claim 1 , wherein the sustained release member is benzyl benzoate.
7 . The composition of claim 1 , wherein the solvent is a mixture of DMSO and glycofurol.
8 . The composition of claim 7 , wherein the volume ratio of DMSO:glycofurol:oil mixture:sustained release member is about 0.9 to about 1.1:about 0.9 to about 1.1:about 0.9 to about 1.1:about 0.9 to about 1.1.
9 . The composition of claim 8 , wherein the volume ratio of DMSO:glycofurol:oil mixture:sustained release member is about 1:about 1:about 1:about 1.
10 . The composition of claim 1 , wherein the fulvestrant concentration is from about 45 mg/ml to about 250 mg/ml.
11 . The composition of claim 10 , wherein the fulvestrant concentration is from about 50 mg/ml to about 150 mg/ml.
12 . The composition of claim 10 , wherein the fulvestrant concentration is from about 100 mg/ml to about 125 mg/ml.
13 . The composition of claim 11 , wherein the fulvestrant concentration is about 50 mg/ml.
14 . The composition of claim 12 , wherein the fulvestrant concentration is about 100 mg/ml.
15 . The composition of claim 1 , wherein the oil mixture is a mixture of caprylic and capric triglycerides.
16 . The composition of claim 1 , having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 36 months of storage at a temperature of from about 5° C. to about 25° C.
17 . The composition of claim 1 , further comprising at least one antioxidant selected from the group consisting of lipoic acid, dihydrolipoic acid, methionine, sulpha-containing amino acids, acetone sodium bisulfate, propyl gallate, butylated hydroxytoluene (“BHT”), butylated hydroxyanisole (“BHA”) and sodium formaldehyde sulfoxylate.
18 . A fulvestrant-containing composition comprising:
a) fulvestrant;
b) DMSO;
c) a mixture of caprylic and capric triglycerides; and
d) benzyl benzoate;
wherein the DMSO is present in an amount of about 33% (v/v), the mixture of caprylic and capric triglycerides is present in an amount of about 25% (v/v), and the benzyl benzoate is present in an amount of about 42% (v/v);
said fulvestrant-containing composition having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.
19. The composition of claim 18 , having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 36 months of storage at a temperature of from about 5° C. to about 25° C.
20 . A fulvestrant-containing composition comprising:
a) fulvestrant;
b) DMSO;
c) a mixture of caprylic and capric triglycerides;
d) benzyl benzoate; and
e) glycofurol;
wherein the volume ratio of DMSO:mixture of caprylic and capric triglycerides:benzyl benzoate:glycofurol is about 1:about 1:about 1:about 1;
said fulvestrant-containing composition having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 24 months of storage at a temperature of from about 5° C. to about 25° C.
21 . The composition of claim 20 , having less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 36 months of storage at a temperature of from about 5° C. to about 25° C.
22 . A method of treating a fulvestrant treatable condition comprising administering to a patient having a fulvestrant treatable condition an effective amount of the composition of claim 1 .
23 . A method of treating a fulvestrant treatable condition comprising administering to a patient having a fulvestrant treatable condition the composition of claim 1 in an amount sufficient to maintain the duration of circulation in the blood stream for at least about 28 days.